← Back to Clinical Trials
Recruiting NCT05548530

NCT05548530 Prognostic Analysis of Different Treatment Options for Cerebral Hemorrhage

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05548530
Status Recruiting
Phase
Sponsor The Affiliated Hospital Of Guizhou Medical University
Condition Brain Hemorrhage
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2014-01-01
Primary Completion 2027-03-25

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Stereotactic intracranial hematoma puncturedecompressive craniectomyNeuroendoscopic

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2014-01-01 with a primary completion date of 2027-03-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To analyze the influence of early hematoma morphology on hematoma expansion, optimize the treatment plan for cerebral hemorrhage, and guide the treatment of patients with cerebral hemorrhage in combination with clinical practice.

Eligibility Criteria

Inclusion Criteria: 1. Age 18-80 years old; 2. Intracerebral hemorrhage was diagnosed by head CT examination; Exclusion Criteria: 1. Multiple intracranial hemorrhage; 2. Intracranial hemorrhage caused by intracranial tumor, aneurysm, trauma, infarction or other lesions; 3. Coagulation disorders or a history of taking anticoagulants; 4. Infectious meningitis, systemic infection; 5. History of severe stroke, heart, kidney, liver and lung dysfunction in the past; 6. Severe brain herniation (mydriasis, respiratory and circulatory failure); 7. Incomplete or missing basic data or follow-up information in the hospital.

Contact & Investigator

Central Contact

Wu guofeng, Doctor

📞 13809431723

Frequently Asked Questions

Who can join the NCT05548530 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Brain Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05548530 currently recruiting?

Yes, NCT05548530 is actively recruiting participants. Visit ClinicalTrials.gov or contact The Affiliated Hospital Of Guizhou Medical University to inquire about joining.

Where is the NCT05548530 trial being conducted?

This trial is being conducted at Guiyang, China.

Who is sponsoring the NCT05548530 clinical trial?

NCT05548530 is sponsored by The Affiliated Hospital Of Guizhou Medical University. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology